AntiCancer’s Oral Methioninase Overcomes Gemcitabine Resistance in Patient-Like Mouse Models of Pancreatic Cancer

“Methioninase can change the paradigm of pancreatic cancer therapy,” said Robert M. Hoffman, Founder of AntiCancer. “Methioninase is active against all cancer types, since they all require excess methionine compared to normal tissue, as seen in the use of radioactive methionine in positron emission tomography (PET) imaging, which gives the strongest PET signal due to the hunger of cancers for methionine,” said Hoffman.

With AntiCancer’s strong patent position on oral methioninase, a very big commercial potential is expected. AntiCancer’s Methuselah Pharmaceuticals subsidiary has been formed to develop oral methioninase as a therapeutic for cancer, diabetes, obesity, hyperhomocysteinemia, and to extend the normal healthy life span.

AntiCancer is also developing engineered bacteria to target all cancer types and has the most patient-like mouse models of cancer, including its PDOX^® models, as well as MetaMouse^®; AngioMouse^®; its histoculture drug response assay (HDRA^®), which is an in vitro test for first-line chemotherapy; and hair-follicle-associated-pluripotent (HAP) stem cells for regenerative medicine. AntiCancer was founded in 1984 with world headquarters in San Diego and subsidiaries in Tokyo, Seoul, Beijing, and Nanjing.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180625005042/en/